Literature DB >> 19925161

Influence of PARP-1 polymorphisms in patients after traumatic brain injury.

Ajit A Sarnaik1, Yvette P Conley, David O Okonkwo, Taura L Barr, Ericka L Fink, Csaba Szabo, Patrick M Kochanek, Robert S B Clark.   

Abstract

Poly(ADP-ribose) polymerase-1 (PARP-1) plays an important role in the cellular response to stress and DNA damage. However, excessive activity of PARP-1 exacerbates brain injury via NAD+ depletion and energy failure. The purpose of this study was to determine if tagging single nucleotide polymorphisms (tSNPs) covering multiple regions of the PARP-1 gene are related to outcome after traumatic brain injury (TBI) in humans. DNA from 191 adult patients with severe TBI was assayed for four tSNPs corresponding to haplotype blocks spanning the PARP-1 gene. Categorization as favorable or poor outcome was based on Glasgow Outcome Scale (GOS) score assigned at 6 months. PARP-1 enzyme activity was indirectly evaluated by quantifying poly-ADP-ribose (PAR)-modified proteins in cerebrospinal fluid (CSF) using an enzyme-linked immunosorbent assay. In multiple logistic regression analysis controlling for age, initial Glasgow Coma Scale score, and gender, the AA genotype of SNP rs3219119 was an independent predictor of favorable neurologic outcome. This SNP tags a haplotype block spanning the automodification and catalytic domains of the PARP-1 gene. SNP rs2271347 correlated with CSF PAR-modified protein level. This SNP, which did not correlate with outcome, tags a haplotype block spanning the promoter region of the PARP-1 gene. We conclude that after severe TBI in humans, a PARP-1 polymorphism within the automodification-catalytic domain is associated with neurological outcome, while a polymorphism within the promoter region was associated with CSF PAR-modified protein level. These findings must be replicated in a prospective study before the relevance of PARP-1 polymorphisms after TBI can be established.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19925161      PMCID: PMC2867630          DOI: 10.1089/neu.2009.1171

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  30 in total

Review 1.  Genetic associations in large versus small studies: an empirical assessment.

Authors:  John P A Ioannidis; Thomas A Trikalinos; Evangelia E Ntzani; Despina G Contopoulos-Ioannidis
Journal:  Lancet       Date:  2003-02-15       Impact factor: 79.321

2.  Effect of poly(ADP-ribose) polymerase inhibitors on the ischemia-reperfusion-induced oxidative cell damage and mitochondrial metabolism in Langendorff heart perfusion system.

Authors:  R Halmosi; Z Berente; E Osz; K Toth; P Literati-Nagy; B Sumegi
Journal:  Mol Pharmacol       Date:  2001-06       Impact factor: 4.436

3.  Innate gender-based proclivity in response to cytotoxicity and programmed cell death pathway.

Authors:  Lina Du; Hülya Bayir; Yichen Lai; Xiaopeng Zhang; Patrick M Kochanek; Simon C Watkins; Steven H Graham; Robert S B Clark
Journal:  J Biol Chem       Date:  2004-07-01       Impact factor: 5.157

4.  Real time quantitative PCR.

Authors:  C A Heid; J Stevens; K J Livak; P M Williams
Journal:  Genome Res       Date:  1996-10       Impact factor: 9.043

5.  Activation of poly(ADP-ribose) polymerase in the rat hippocampus may contribute to cellular recovery following sublethal transient global ischemia.

Authors:  T Nagayama; R P Simon; D Chen; D C Henshall; W Pei; R A Stetler; J Chen
Journal:  J Neurochem       Date:  2000-04       Impact factor: 5.372

6.  Intra-mitochondrial poly(ADP-ribosylation) contributes to NAD+ depletion and cell death induced by oxidative stress.

Authors:  Lina Du; Xiaopeng Zhang; Yong Y Han; Nancy A Burke; Patrick M Kochanek; Simon C Watkins; Steven H Graham; Joseph A Carcillo; Csaba Szabó; Robert S B Clark
Journal:  J Biol Chem       Date:  2003-03-07       Impact factor: 5.157

Review 7.  ADP-ribosylation.

Authors:  K Ueda; O Hayaishi
Journal:  Annu Rev Biochem       Date:  1985       Impact factor: 23.643

Review 8.  The therapeutic potential of poly(ADP-ribose) polymerase inhibitors.

Authors:  László Virág; Csaba Szabó
Journal:  Pharmacol Rev       Date:  2002-09       Impact factor: 25.468

Review 9.  The PARP superfamily.

Authors:  Jean-Christophe Amé; Catherine Spenlehauer; Gilbert de Murcia
Journal:  Bioessays       Date:  2004-08       Impact factor: 4.345

10.  A dual role for poly-ADP-ribosylation in spatial memory acquisition after traumatic brain injury in mice involving NAD+ depletion and ribosylation of 14-3-3gamma.

Authors:  Margaret A Satchell; Xiaopeng Zhang; Patrick M Kochanek; C Edward Dixon; Larry W Jenkins; John Melick; Csaba Szabó; Robert S B Clark
Journal:  J Neurochem       Date:  2003-05       Impact factor: 5.372

View more
  13 in total

Review 1.  A review of neuroprotection pharmacology and therapies in patients with acute traumatic brain injury.

Authors:  Kevin W McConeghy; Jimmi Hatton; Lindsey Hughes; Aaron M Cook
Journal:  CNS Drugs       Date:  2012-07-01       Impact factor: 5.749

Review 2.  Genetics and outcomes after traumatic brain injury (TBI): what do we know about pediatric TBI?

Authors:  Brad Kurowski; Lisa J Martin; Shari L Wade
Journal:  J Pediatr Rehabil Med       Date:  2012

3.  Increased poly(ADP-ribosyl)ation in skeletal muscle tissue of pediatric patients with severe burn injury: prevention by propranolol treatment.

Authors:  Gábor Oláh; Celeste C Finnerty; Elena Sbrana; Itoro Elijah; Domokos Gerö; David N Herndon; Csaba Szabó
Journal:  Shock       Date:  2011-07       Impact factor: 3.454

4.  Role of Bax in death of uninfected retinal cells during murine cytomegalovirus retinitis.

Authors:  Juan Mo; Brendan Marshall; Jason Covar; Nancy Y Zhang; Sylvia B Smith; Sally S Atherton; Ming Zhang
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-10-08       Impact factor: 4.799

5.  Paths to Successful Translation of New Therapies for Severe Traumatic Brain Injury in the Golden Age of Traumatic Brain Injury Research: A Pittsburgh Vision.

Authors:  Patrick M Kochanek; Travis C Jackson; Ruchira M Jha; Robert S B Clark; David O Okonkwo; Hülya Bayır; Samuel M Poloyac; Amy K Wagner; Philip E Empey; Yvette P Conley; Michael J Bell; Anthony E Kline; Corina O Bondi; Dennis W Simon; Shaun W Carlson; Ava M Puccio; Christopher M Horvat; Alicia K Au; Jonathan Elmer; Amery Treble-Barna; Milos D Ikonomovic; Lori A Shutter; D Lansing Taylor; Andrew M Stern; Steven H Graham; Valerian E Kagan; Edwin K Jackson; Stephen R Wisniewski; C Edward Dixon
Journal:  J Neurotrauma       Date:  2019-02-01       Impact factor: 5.269

6.  Applying Systems Biology Methodology To Identify Genetic Factors Possibly Associated with Recovery after Traumatic Brain Injury.

Authors:  Brad G Kurowski; Amery Treble-Barna; Alexis J Pitzer; Shari L Wade; Lisa J Martin; Ranjit S Chima; Anil Jegga
Journal:  J Neurotrauma       Date:  2017-05-03       Impact factor: 5.269

Review 7.  Activation of PARP by oxidative stress induced by β-amyloid: implications for Alzheimer's disease.

Authors:  Rosella Abeti; Michael R Duchen
Journal:  Neurochem Res       Date:  2012-10-18       Impact factor: 3.996

Review 8.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

9.  Uncovering precision phenotype-biomarker associations in traumatic brain injury using topological data analysis.

Authors:  Jessica L Nielson; Shelly R Cooper; John K Yue; Marco D Sorani; Tomoo Inoue; Esther L Yuh; Pratik Mukherjee; Tanya C Petrossian; Jesse Paquette; Pek Y Lum; Gunnar E Carlsson; Mary J Vassar; Hester F Lingsma; Wayne A Gordon; Alex B Valadka; David O Okonkwo; Geoffrey T Manley; Adam R Ferguson
Journal:  PLoS One       Date:  2017-03-03       Impact factor: 3.240

Review 10.  Repositioning PARP inhibitors for SARS-CoV-2 infection(COVID-19); a new multi-pronged therapy for acute respiratory distress syndrome?

Authors:  Nicola Curtin; Krisztián Bányai; James Thaventhiran; John Le Quesne; Zsuzsanna Helyes; Péter Bai
Journal:  Br J Pharmacol       Date:  2020-07-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.